C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curative Resection for Pancreatic Cancer

Abstract

Aim: Prognostic factors of recurrence and survival in various cancer types have been reported and include Creactive protein (CRP)-based measures as evidenced by the Glasgow prognostic score (GPS), as well as peripheral blood cell-based prognostic values such as the prognostic index (PI), neutrophil-to-lymphocyte ratio (NLR), and platelet-tolymphocyte ratio (PLR). The aim of this study was to identify significant prognostic values and compare them for suitability for use in patients after curative pancreatic resection for pancreatic cancer. Materials and Methods: Between 2000 and 2015, 188 patients were enrolled in this retrospective study. The relationship between clinicopathological variables including various prognostic values and disease-free (DFS) and overall (OS) survival was investigated by univariate analysis. The area under the receiver operating characteristics curve (AUC) was evaluated to compare the predictive ability of each of these scoring systems. Multivariate analysis was then performed to identify clinicopathological variables that associated DFS and OS. Results: In univariate analysis, GPS, modified GPS, CRP to albumin ratio and PI were significant risk factors for both DFS and OS. The AUC of CRP-based scores (GPS, modified GPS, and CRP to albumin ratio) were consistently larger in comparison with PI, which consists of both CRP and peripheral blood cell scores, at all time points for both DFS and OS. In multivariate analysis, GPS was the only independent risk factor of tumor recurrence and survival. Conclusion: CRP-based prognostic scores have an independent

Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer

“…C-reactive protein) [1,19]. A meta-analysis of 34 studies including 7105 patients with pancreatic cancer revealed that high PLR and NLR were defined as values from 150 to 200, and 2 to 5, respectively [20].…”

The Prognostic Value of Modified Glasgow Prognostic Score in Pancreatic Cancer: A Meta-analysis

“…Ultimately, 20 studies [8,[15][16][17][18][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] including 6512 patients were enrolled in this meta-analysis after excluding ineligible studies.…”

The Prognostic Value of Modified Glasgow Prognostic Score in Pancreatic Cancer: A Meta-analysis

“…1, the literature search process was summarized in the ow diagram according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) [23]. Ultimately, 20 studies [8,[15][16][17][18][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] including 6512 patients were enrolled in this meta-analysis after excluding ineligible studies.…”